Ascendis Pharma AS (ASND NASDAQ) stock market data APIs
$271.8814
-2.93(-1.1%)
as of July 2, 2026
Try our APIs with
free plan!
Ascendis Pharma AS Financial Data Overview
Price chart is built with
Anychart
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Prev. Close
271.8814
Open
268.9471
High
272.2471
Low
263.8059
52 wk Range
160.86-274.89
Market Cap
18 005 M
P/E Ratio
31.8445
Shares Outstanding
65 593 K
Revenue
866 M
EPS
0.27
Beta
0.485
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ascendis Pharma AS (top by weight)
Ticker
100-day Price Change
Weight
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
1.46
(24%)
8.76
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma AS data using free add-ons & libraries
Get Ascendis Pharma AS Fundamental Data
Ascendis Pharma AS Fundamental data includes:
- Net Revenue: 866 M
- EBITDA: -10 224 000
- Earnings Per Share: 8
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: 0.43
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma AS News
New
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Ascendis Pharma Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observ...
Big Pharma Has a Case of Merger Mania
In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what’s driving the merger-and-acquisition frenzy, includin...
Ascendis Presents Pivotal ApproACH And Phase 2 COACH Trial Data In Achondroplasia At ICCBH 2026
(RTTNews) - Ascendis Pharma A/S (ASND), a commercial-stage biopharmaceutical company, announced that it will present data from the recently completed pivotal ApproaCH trial of YUVIWEL and the Phase 2 ...
Ascendis Pharma added to Russell 3000, Russell 1000 and other U.S. indexes
Ascendis Pharma (ASND [https://seekingalpha.com/symbol/ASND]) said [https://seekingalpha.com/pr/20565715-ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1000-russell] on...
Get Ascendis Pharma AS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
